The use of adjusted ideal body weight for overweight patients undergoing HPC mobilisation for autologous transplantation
- 569 Downloads
Generally, patients’ actual body weight (ABW) is used to calculate the number of CD34+ cells to be harvested for autologous haematopoietic progenitor cell (HPC) transplantation. In our institution, ‘overweight’ patients weighing at least 25 % more than their ideal body weight (IBW) have their adjusted ideal body weight (AdjIBW) used for determination of blood volume to be processed to achieve a minimum target of CD34+ cells per kilogram, as well as CD34+ cell dosage calculation at transplant. AdjIBW is calculated as follows: AdjIBW = IBW + 0.25 × (actual weight − IBW). We have used AdjIBW for 65/153 patients who have had autologous HPC harvests, with a median AdjIBW of 69 kg (range, 50–110 kg). Median actual weight was 90 kg (range, 62–175 kg). Median volume of peripheral blood processed to achieve a minimum 2 × 106 CD34+ cells/kg for these patients was 13.2 L (range, 5–35 L), and the median CD34+ cells × 106/kg collected for AdjIBW was 6.3 (range, 1.7–33). For normal-weight patients (n = 88; median ABW, 75 kg; range, 49–98 kg), the corresponding median apheresis volume was 16 L (range, 7–24 L), and median CD34+ cells × 106/kg harvested was 4.5 (range, 1.4–15.9). In total, 35 in a total transplant cohort of 82 patients had AdjIBW used to determine CD34+ cell dose at time of transplant, with a median of 4.5 × 106/kg, (if their ABW was used in the calculation; 3.1 × 106/kg), compared to median dose of 3.2 × 106/kg ABW for the normal-weight patient cohort. All patients engrafted with no significant difference between median times to neutrophil and platelet engraftment for the overweight (13 and 15 days, respectively) compared with normal-weight (12 and 14 days, respectively) patient cohorts. We conclude that the use of AdjIBW is a useful tool for successful harvest and subsequent transplant for overweight patients, with no adverse effect on engraftment times.
KeywordsIdeal body weight Actual body weight Adjusted ideal body weight CD34+ cell dose Engraftment
Conflict of interest
The authors declare no conflict of interest.
- 2.The ABMTRR Steering Committee of the BMTSANZ Australian Bone Marrow Transplant Recipient Registry (ABMTRR) Annual Data Summary 2008Google Scholar
- 3.Pasquini MC, He V, Perez WS (2006) CIBMTR summary slides part 1. CIBMTR Newsletter 12:5–7Google Scholar
- 4.Bessinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al (1995) Factors that influence collection and engraftment of autologous peripheral blood-stem cells. J Clin Oncol 13:2547–2555Google Scholar
- 10.Australian Bureau of Statistics 4364.0 National Health Survey: Summary of Results, 2007–08. Reissued 2009Google Scholar
- 15.Devine BJ (1974) Gentamicin therapy. Drug Intel Clin Phar 8:650–655Google Scholar
- 19.Maclean PS, Parker AN, McQuaker IG, Clark AD, Farrell E, Douglas KW (2007) Ideal body weight correlates better with engraftment after PBSC autograft then actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant 40:665–669PubMedCrossRefGoogle Scholar
- 23.Ungerstedt JS, Waltz E, Uttervall K, Johansson B-M, Wahlin BE, Nassman P et al (2011) Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and haematological recovery. Med Oncol. doi: 10.1007/s12032-011-0029-3